Edesa Biotech, Inc.

NASDAQ:EDSA

Biotechnology

Healthcare
$5.75 +1.31%

+$0.09 today

Market cap
$55.39M
Beta
1.07
P/E (TTM)
-5.5
EPS (TTM)
-$1.27
52W Low $0.72High $20.32

Volume 0.07M

Average 0.62M

Returns on capital

Edesa Biotech, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-57.7%

avg -101.2%

ROIC

-63.5%

avg -113.4%

ROA

-53.1%

avg -75.7%

Analysis

ROA is currently the strongest return metric at -53.1% versus its period average of -75.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Pardeep Nijhawan FRCPC

Chief Executive Officer, Company Secretary & DirectorUSD 483.83K55——

Michael J. Brooks

PresidentUSD 450.21K47291.48K3.28%

Peter John Weiler

Chief Financial OfficerUSD 310.56K57——

Compensation is shown in the reported currency; data updated Jul 25, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 27, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

8

$226,455.15

Sells

0

$0.00

Net Transaction Value

+$226,455.15

Net buying

Most Active

Nijhawan Pardeep

7 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Mar 5, 26

Nijhawan Pardeep

Indirect

Buy$39K
Mar 4, 26

Nijhawan Pardeep

Indirect

Buy$42.6K
Mar 3, 26

Nijhawan Pardeep

Indirect

Buy$36.3K
Mar 2, 26

Nijhawan Pardeep

Direct

Buy$4K
Mar 2, 26

Nijhawan Pardeep

Indirect

Buy$2.3K
Feb 27, 26

Nijhawan Pardeep

Indirect

Buy$66.7K
Feb 26, 26

Brooks Michael J

Direct

Buy$3.1K
Feb 26, 26

Nijhawan Pardeep

Direct

Buy$32.5K

Summary

Insiders reported 8 buys worth $226,455.15 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $226,455.15. Nijhawan Pardeep was the most active insider with 7 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Edesa Biotech, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Competitors

Peer companies in the same sector

Health

Questions

Management questions

Common questions about EDSA's management, answered from reported figures.

Who manages EDSA?

Edesa Biotech, Inc. (EDSA) lists 3 active executives. The top listed executive is Peter John Weiler, Chief Financial Officer.

Are EDSA insiders buying or selling?

Recent insider activity shows net buying of $9.04M.